Neurodegenerative Drugs Market to Reach $45 Billion by 2022 Worldwide - Growth Driven by an Aging Population, the Approval of Novel Immunomodulators and Neuromodulators

ResearchMoz added Latest Research Report titled " Global Neurodegenerative Drugs Market to 2022 - Growth Driven by an Aging Population, the Approval of Novel Immunomodulators and Neuromodulators, and Strong Uptake of Marketed Anti-Inflammatory Treatments " to it's Large Report database.

Neurodegenerative disorders are a cluster of conditions that affect the central nervous system. They include both hereditary and sporadic conditions that are characterized by slow, irreversible, progressive dysfunction of the nervous system with the increasing degeneration of neurons, which causes symptoms such as motor impairment, memory loss and declining cognitive ability. Neurodegenerative disorders cannot currently be cured, and treatment is aimed at managing the disease indication in order to reduce the severity of symptoms and slow progression.

The report focuses on five key indications within neurodegenerative disorders: Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis and multiple sclerosis. With no curative therapies available, symptomatic medications prescribed off-label are an important part of the treatment paradigm, especially in amyotrophic lateral sclerosis and multiple sclerosis. This indicates the need for extensive R&D within this area.

Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=938605

Immunomodulators are the most effective and most common therapies used in neurodegenerative disorders. This class of compounds has been the most commercially successful in the past decade, particularly in the multiple sclerosis market, with many clinical trials underway for amyotrophic lateral sclerosis. The market for neurodegenerative disorders is largely accounted for by premium products, with generic products holding only a relatively small share. However, some generic products have been able to secure sizable market shares after the patent expiries of leading drugs. Glatopa (a generic version of Copaxone) recently entered the market and is expected to reach sales of $233m within the forecast period.

Although there is a high degree of failure and uncertainty within the R&D of neurodegenerative disorder drugs, the number of drugs in the pipeline is very high, at 1,494. The majority of pipeline products are novel active pharmaceutical ingredients, with only a small proportion of products being either generics or repositioned from other indications. This shows progression in terms of the variety of molecules being developed as therapeutic agents within the neurodegenerative disorders pipeline. The market is expected to grow over the forecast period, which is attributed to the approval of new drugs, as well as the increasing aging population.

Read All Pharmaceutical Market Research Reports @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html

Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7

2 Introduction 10
2.1 Therapy Area Introduction 10
2.1.1 Alzheimer’s Disease 10
2.1.2 Parkinson’s Disease 11
2.1.3 Huntington’s Disease 11
2.1.4 Amyotrophic Lateral Sclerosis 12
2.1.5 Multiple Sclerosis 13
2.2 Symptoms 14
2.3 Etiology and Pathophysiology 15
2.3.1 Pathophysiology 18
2.4 Epidemiology Patterns: Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates 22
2.4.1 Alzheimer’s Disease 23
2.4.2 Parkinson’s Disease 24
2.4.3 Huntington’s Disease 25
2.4.4 Amyotrophic Lateral Sclerosis 26
2.4.5 Multiple Sclerosis 27
2.5 Co-morbidities and Complications 28
2.6 Treatment 29
2.6.1 Alzheimer’s Disease 29
2.6.2 Parkinson’s Disease 30
2.6.3 Huntington’s Disease 33
2.6.4 Amyotrophic Lateral Sclerosis 33
2.6.5 Multiple Sclerosis 33

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/

This release was published on openPR.